The broad use of RNA-sequencing technologies held a promise of improved diagnostic tools based on comprehensive transcript sets. However, mining human transcriptome data for disease biomarkers in clinical specimens is restricted by the limited power of conventional reference-based protocols relying on uniquely mapped reads and transcript annotations. Here, we implemented a blind reference-free computational protocol, DE-kupl, to directly infer RNA variations of any origin, including yet unreferenced RNAs, from high coverage total stranded RNA-sequencing datasets of tissue origin. As a bench test, this protocol was powered for detection of RNA subsequences embedded into unannotated putative long noncoding (lnc)RNAs expressed in prostate cancer tissues. Through filtering and visual inspection of 1,179 candidates, we defined 21 lncRNA probes that were further validated for robust tumorspecific expression by NanoString single molecule-based RNA measurements in 144 tissue specimens. Predictive modeling yielded a restricted probe panel enabling over 90% of true positive detection of cancer in an independent dataset from The Cancer Genome Atlas. Remarkably, this clinical signature made of only 9 unannotated lncRNAs largely outperformed PCA3, the only RNA biomarker approved by the Food and Drug Administration agency, specifically, in detection of high-risk prostate tumors. The proposed reference-free computational workflow is modular, highly sensitive and robust and can be applied to any pathology and any clinical application.
Abstract
The broad use of RNA-sequencing technologies held a promise of improved diagnostic tools based on comprehensive transcript sets. However, mining human transcriptome data for disease biomarkers in clinical specimens is restricted by the limited power of conventional reference-based protocols relying on uniquely mapped reads and transcript annotations. Here, we implemented a blind reference-free computational protocol, DE-kupl, to directly infer RNA variations of any origin, including yet unreferenced RNAs, from high coverage total stranded RNA-sequencing datasets of tissue origin. As a bench test, this protocol was powered for detection of RNA subsequences embedded into unannotated putative long noncoding (lnc)RNAs expressed in prostate cancer tissues. Through filtering and visual inspection of 1,179
candidates, we defined 21 lncRNA probes that were further validated for robust tumorspecific expression by NanoString single molecule-based RNA measurements in 144 tissue specimens. Predictive modeling yielded a restricted probe panel enabling over 90% of true positive detection of cancer in an independent dataset from The Cancer Genome Atlas. Remarkably, this clinical signature made of only 9 unannotated lncRNAs largely outperformed PCA3, the only RNA biomarker approved by the Food and Drug Administration agency, specifically, in detection of high-risk prostate tumors. The proposed reference-free computational workflow is modular, highly sensitive and robust and can be applied to any pathology and any clinical application.
INTRODUCTION
RNA sequencing (RNA-seq) has revolutionized our knowledge of human transcriptome and has been implemented as a pivot technique in clinical applications for the discovery of RNA-based biomarkers allowing disease diagnosis, prognosis and therapy follow-up.
However, most biomarker discovery pipelines are blind to uncharacterized RNA molecules since they rely on the alignment of uniquely mapped reads to annotated references of the human transcriptome which are far from complete (UszczynskaRatajczak et al. 2018) , (Deveson et al. 2018) , (Morillon and Gautheret 2019) . Indeed, state-specific unspliced variants, rare mRNA isoforms, RNA hybrids originating from trans-splicing or genome rearrangements, unannotated intergenic or antisense noncoding RNAs, mobile elements or viral genome insertions would be systematically missed. A recent approach to RNA-seq data analysis, DE-kupl, combines k-mer (subsequences of fixed size) decomposition and differential expression analysis to discover transcript variations yet unreferenced in the human transcriptome (Audoux et al. 2017 ). Applied to poly(A)+ RNA-seq datasets of in vitro cell system, DE-kupl unveiled a large number of RNA subsequences embedded into novel long noncoding RNAs. These transcripts of more than 200 nucleotides in length transcribed by RNA polymerase II from intergenic, intronic or antisense noncoding genomic locations constitute a prevalent class of human genes. Some lncRNAs are now recognized as precisely regulated stand-alone molecules participating in the control of fundamental cellular processes (Jarroux et al. 2017) , (Quinn and Chang 2015) . They show aberrant and specific expression in various cancers and other diseases promoting them as biomarkers, therapeutic molecules and drug targets (Leucci 2018) , (Van Grembergen et al. 2016) . Importantly, some lncRNAs can be robustly detected in biological fluids (blood and urine) as circulating molecules or encapsulated into extracellular vesicles, hence, raising an attractive possibility of lncRNA biomarkers usage in non-invasive clinical tests (Silva et al. 2015) , (Deng et al. 2017) , , (Zhao et al. 2018a ), (Wang et al. 2018 ). The only example of an RNA-based biomarker so far introduced in clinical practice is the PCA3 lncRNA in prostate cancer (PCa) (de Kok et al. 2002) . PCA3 is transcribed antisense to the tumor suppressor PRUNE2 gene and promotes its premessenger RNA editing and degradation (Salameh et al. 2015) . Being overexpressed in 95% of PCa cases, PCA3 is detected in urines and helps diagnosis providing, in addition to other clinical tests, more accurate metrics regarding repeated biopsies (Groskopf et al. 2006) , (Galasso et al. 2010 ). However, it remains inaccurate in discrimination between low-and high-risk tumors since its expression may dramatically decrease in aggressive PCa cases tempering its systematic usage (Loeb and Partin 2011) , (Alshalalfa et al. 2017 ).
Since PCA3 discovery and the development of RNA-seq technologies, the PCa transcriptome has been extensively explored by The Cancer Genome Atlas (TCGA) consortium and others to identify numerous PCa-associated lncRNAs (PCAT family) such as PCAT1, PCAT7 or PCAT114/SChLAP1 (Iyer et al. 2015) , (Prensner et al. 2014 ).
However, none of them has been yet introduced into clinical practice because of the variable expression incidence, as for SChLAP1 detected in 25% of PCa cases presenting metastatic traits (Prensner et al. 2013) , or low specificity, as PCAT1 or PCAT7, thus infringing their clinical value. Additional efforts are required for more accurate and exhaustive RNA identification, as well as more rigorous validations of clinical potency through independent RNA measurement technologies and clinical cohorts. Regardless a large number of transcriptomic studies and variety of clinical samples analyzed, discovery of RNA-based molecular biomarkers from publicly available RNA-seq datasets is still limited at two levels: (i) most experimental setups are based on poly(A) selected, unstranded cDNA sequencing, and (ii) computational analyses are generally focused on annotated genes and full-length RNA assemblies. This impedes the detection of low and poorly polyadenylated RNAs but also partially degraded RNAs from formalin-fixed paraffin-embedded (FFPE) tissues or other clinical samples (Zhao et al. 2018b) , (Zhao et al. 2014) . In addition, RNA-seq reads counting is less accurate at 5' RNA ends or even impossible for co-expressed paired sense/antisense transcripts and for yet unannotated RNAs among noncoding, fusion, repeat-derived transcripts (Audoux et al. 2017) , (Davila et al. 2016) .
Here, we propose a conceptually novel exploratory framework combining the total stranded RNA-seq of clinical samples and the reference-free DE-kupl algorithm for discovery of novel tumor-specific transcript variations. As a proof-of-concept, we focused on the least explored, noncoding portion of the genome devoid of annotated protein-coding sequences to build an exhaustive catalog of PCa associated subsequences (contigs) embedded into lncRNA genes. The catalog was further refined through minimal filtering to isolate the most potent subset of contigs and validate 21 of them by an alternative NanoString assay in the extended cohort of 144 prostate specimens. From this, a predictive modeling derived a panel of 9 yet unannotated lncRNAs validated for robust expression in an independent TCGA cohort. Importantly, its clinical performance surpassed the PCA3 lncRNA specifically in discrimination of high-risk tumors. The proposed probe-set can be further used for development of a PCa diagnostic test.
Moving beyond this point, the proposed computational and experimental platform may serve as a tool for biomarkers discovery for any disease and any clinical task aiming at improved medical care and development of precision medicine approaches.
RESULTS

Identification of PCa-specific RNA variants in the Discovery Set by DE-kupl
The biomarker discovery workflow included three major phases: discovery, selection and validation (Fig. 1) . First, for discovery, we performed a deep total stranded RNA-seq of ribosomal RNA-depleted RNA samples isolated from prostate tissues after radical prostatectomy (Discovery Set, PAIR cohort, Supplemental Table S1 ). This Discovery set was processed by DE-kupl to identify tumor-specific transcripts. DE-kupl directly queries FASTQ files for subsequences (k-mers) with differential counts/expression (DE) between two conditions ( Fig. 2A) (Audoux et al. 2017) . Overlapping k-mers are then assembled into contigs and, in a final step, mapped to the human genome for annotation.
In the aim to focus exclusively on novel, yet unannotated RNA elements, k-mers exactly matching GENCODE annotated transcripts were masked. We eventually retained contigs longer than 200 nucleotides and showing adjusted p-values below 0.01 to capture the most significant expression changes linked either to new transcriptional or processing events within known or putative lncRNA loci. With these criteria, we identified 1,179 tumor up-regulated contigs assigned to four main categories according to their mapping features: contiguous (uniquely mapped) contigs (N=935), splice variants (N=54), repeats (N=167) and unmapped contigs (N=23) (Fig. 2B, Fig. S1 CTBP1-AS (ctg_25348, P10). The rest mapped to intergenic noncoding locations or antisense to referenced protein-coding or noncoding genes (Fig. 2C ). An unsupervised clustering of prostate specimens based on contigs expression counts allowed proper discrimination of tumor from normal tissues of the Discovery Set (Fig. 2D ).
In conclusion, DE-kupl identified thousands of PCa-associated RNA variants for the majority embedded into yet unreferenced transcripts which may represent putative novel lncRNAs. This depository was further explored for clinical relevance. 
Naïve assembly of Transcription Units identifies novel prostate cancer associated lncRNAs
To complement the reference-free protocol, we applied a reference-based protocol to build a catalog of lncRNAs from the same Discovery Set. Total RNA-seq produces much more intronic and exon-exon junction reads than poly(A)-selected RNA-seq, which is deleterious for splice graph-based assemblers such as Cufflinks (Kukurba and Montgomery 2015) , (Hayer et al. 2015a ). To bypass this difficulty, we developed a more straightforward lncRNA annotation pipeline, HoLdUp, which identifies transcription units (TU) based on coverage analysis (Fig. 3A) . In this workflow, uniquely mapped reads were assembled into TUs and mapped to the GENCODE annotation to extract intergenic and antisense lncRNAs (see Methods for details). They were further ranked according to their expression level, presence of splice junctions and existence of matched expressed sequence tags (EST). In total, we retained 168,163 TUs with abovethreshold expression of 0.2 quartile of mRNA expression (Class 2) and, within this group, the most robust 2,972 TUs with at least one splice junction and one EST (Class 1) (Fig. 3B) . Globally, newly detected transcripts were as much expressed as GENCODE annotated lncRNAs but lower than mRNAs ( Intersection of DE-kupl contigs with HoLdUp TUs and the recent GENCODE lncRNA annotation showed that 687 DE-kupl contigs out of 1,179 make part of the stand-alone transcripts. Moreover, up to 85.5% and 96.8% DE-kupl contigs embedded into GENCODE and HoLdUp Class 1 lncRNA genes, respectively, were also detected by DESeq as significantly up-regulated transcripts in the same dataset, when the RNA-seq reads were counted within the entire TU ( Fig. 3C; Fig. S2C ). One such example is the contig
Normal ( 88 (85) 354 (309) 5 (5) 29 (27) 0 14 (3) 3 (3) 94 ( 1 (1) 165 (157) 14 (9) 12 (4) 2 (2) ctg_23999 (P22) embedded into a novel HoLdUp assembled Class 1 TU antisense to the protein-coding FBXL7 gene (Fig. 3D ).
In conclusion, the reference-based assembly protocol HoLdUp is complementary to DEkupl and allows attributing short RNA subsequences to whole transcription units.
Nevertheless, DE-kupl was more powerful illuminating much more transcriptomic variations not only within the annotated loci but also within putative new noncoding regions in highly complex and heterogeneous total RNA-seq datasets of clinical origin.
Selection of a restricted set of 23 PCa RNA contigs showing the highest differential expression
We further leveraged the DE-kupl contig catalog to define a robust PCa signature among putative new lncRNAs using several filters (Fig. S3A) . First, contigs were sorted according to their adjusted p-value and, second, were visually selected using the Integrative Genomic Viewer (IGV) applying the following criteria: (i) when several contigs were present within the same genomic region (5 kilobase window) the contig with the lowest adjusted p-value was retained, (ii) contigs antisense to expressed exons, bidirectional or positioned in close vicinity to other transcribed protein-coding genes were filtered out. We also retained contigs assigned to already known PCa associated lncRNAs, such as CTBP1-AS (ctg_25348, P10), PCAT7 (ctg_111158, P6) and PCAT1 (ctg_105149, P18), or lncRNAs referenced elsewhere as ctg_104447 (P11) mapped into LOC283177, ctg_123090 (P5) into AC004066.3, and ctg_73782 (P8) into LINC01006; all of which passed the aforementioned selection criteria. Notably, the RNA-seq visualization of a new contig antisense to the protein-coding FBP2 gene (ctg_28650, P2)
revealed that it most likely makes part of the PCAT7 lncRNA as an extension of its last exon (Fig. S3B) . The contig ctg_28650 (P2) was retained in the restricted list as the strongest candidate antisense to FBP2, overcoming ctg_111158 (P6) assigned to the PCAT7 gene. In total, 23 candidates belonging to contiguous (N=21), spliced (N=1) or repeat (N=1) subgroups of contigs were selected for further validation, all being expressed at least 6 times more in tumor tissues comparing to normal prostate (Fig. S3C , Supplemental Table S2 ). Following the manual filtering we aimed to validate the expression of selected 23 contigs in the extended PAIR cohort of 9 normal and 135 tumor specimens (Selection Table S3 ). For this purpose, an alternative RNA quantification procedure based on the NanoString nCounter TM platform for direct enzyme-free multiplex digital RNA measurements was carried out (Fig. 4A) . In addition to DE-kupl contigs, a probe for PCA3 was used as a benchmark lncRNA. We also measured the expression of six housekeeping genes and selected three lowly expressed mRNAs (GPATCH3, ZNF2, ZNF346) as custom internal controls for relative quantifications (Supplemental Table S4 , Fig. S4 ).
The NanoString assay revealed that all DE-kupl contigs were expressed at a lower level than PCA3, but still 21 out of 23 contigs were significantly overexpressed (Wilcoxon pvalue < 0.01) in tumor specimens (Fig. 4A , Supplemental Table S5 ). Two contigs, intergenic P22 (ctg_119680) and repeat P17 (ctg_36195) did not show significant difference in expression between normal and tumor specimens. Ranking according to pvalues revealed 12 contigs better than PCA3. Among the top DE contigs were those embedded into PCAT1 (ctg_105149, P18), CTBP1-AS (ctg_25348, P10) and PCAT7 (ctg_111158, P6) genes, and the rest were assigned to novel lncRNAs. Notably, apart from P17 (ctg_36195) and P22 (ctg_119680), expression measurements were consistent between the two technologies, total stranded RNA-seq and NanoString, though the pvalues ordering was different (Fig. S5 , Supplemental Table S6 ).
Thus, 21 out of 23 contigs were validated in the extended set of RNA specimens using the independent single-molecule measurement technology. Figure S4 . Box-plot of Log10(counts) of housekeeping protein-coding genes in 9 normal and 135 tumor specimens of the PAIR cohort (Selection Set) by the NanoString nCounter assay.
Selection Set, PAIR NanoString Table S7 ).
The occurrence of sequences representing 23 DE-kupl contigs was measured and compared to PCA3. In total, 16 out of 23 DE-kupl contigs had significant support for overexpression in tumor specimens in the TCGA-PRAD cohort (Wilcoxon p-value < 0.01, Table S8 ). Among the best scored candidates, the two novel DE-kupl contigs, P16 (ctg_111348) antisense to DLX1 and intergenic P1 (ctg_17297), surpassed PCA3 ranked third. However, important discrepancies were observed between expression counts in poly(A)+ RNA-seq TCGA datasets and NanoString or total RNA-seq PAIR datasets. First, P22 (ctg_119680) was detected as DE in TCGA-PRAD, but failed the DE test when measured by NanoString (Fig. 4, Fig. S5) . 
Expression of DE-kupl contigs is independent on tumor risk and recurrence metrics
Several clinical studies have revealed high heterogeneity of expression and low efficiency of the PCA3 biomarker in detection of high-risk tumors, questioning its robustness and reliability in PCa diagnostics (Alshalalfa et al. 2017) , (Fenstermaker et al. 2017 ). We assessed contig expression in tumors of different clinical metrics. For risk prognosis, the most common metric is a three-group risk stratification system established by D'Amico in 1998 (D'Amico et al. 1998) , which takes into account preoperative PSA level, biopsy Gleason score and clinical TNM stage. As mentioned above, this scheme is highly debated due to disagreements over the PSA score in relation to PCa over-diagnosis (Loeb et al. 2014) , (Carlsson et al. 2012 ). To define a molecular signature independent of PSA, we excluded this criterion and categorized tumor specimens into low-, intermediate-and high-risk groups uniquely on the basis of Gleason and TNM features, below referred to as naïve indexing (Fig. S6) . In addition to risk assessment, we also separated specimens in two subgroups depending on the tumor recurrence status (Fig. S6B) . Then, expression of PCA3 and the 23 DE-kupl contigs were compared for each subgroup of the Selection Set. To evaluate the robustness of contig expression, we ranked probes by decreasing FC for high-risk (HR) against low-risk (LR) tumors and positive versus negative recurrence status (Fig. 5) . The majority of contigs showed robust expression independently of the tumor classification. In contrast, the PCA3 level was more disperse with the lower median and mean expression and higher p-values in high-risk and recurrence positive specimens (Supplemental Table S9 ). While considering only 21 significantly overexpressed contigs, 17 of them outperformed PCA3 in both contrasts (Supplemental Table S9 ). Notably, contigs P6 (ctg_111158) and P2 (ctg_28650) both antisense to FBP2, P10 (ctg_25348) embedded into CTBP1-AS, but also the novel P16 contig (ctg_111348) antisense to DLX1 and the intergenic P1 (ctg_17297) performed best.
In conclusion, the majority of DE-kupl contigs showed robust expression independent of tumor metrics. Hence, even if used alone, they may offer a better clinical potency for PCa diagnosis than PCA3.
Inferring a multiplex RNA-probe panel and evaluation of its performance in PCa diagnosis
Figure S7 To extract parsimonious probe subsets predicting the tumor status, we applied LASSO (Least Absolute Shrinkage and Selection Operator) logistic regression on the Selection Set of 144 PAIR specimens (Ghosh and Chinnaiyan 2005) . First, the initial 21 DE-kupl contigs and PCA3 validated for expression by NanoString were submitted to LASSO to define the best mixed signature comprised of already known and yet unannotated lncRNA probes for discrimination of tumor from normal tissues (Fig. S7A) . Then, LASSO was performed with the probe subset composed uniquely of contigs assigned to putative novel lncRNAs (N=15) to infer the best new-lnc RNA signature. It resulted in two panels of 9 mixed and 9 new-lnc RNA candidates (Fig. 6A, Fig. S7B Fig. 6B and 6C ). In addition, these signatures were much better in predicting high-risk tumors where PCA3 is particularly inaccurate (Fig. 6C) . Remarkably, the newlnc RNA signature of 9 contigs composed uniquely of yet unannotated lncRNAs predicted the tumor status with the same performance as the mixed signature. Logistic regression did not retain PCA3 within the mixed signature set, instead contigs embedded into the well characterized PCAT1 lncRNA and into two already annotated but yet functionally uncharacterized lncRNAs LOC283177 and LINC01006 were present. P1  P1  P2  P2  P3  P7  P7  P8  P11  P12  P14  P18  P20  P20  P23 PCA3  P1  ctg_17297 ctg_17297  P2  ctg_28650 ctg_28650  P3  ctg_57223 ctg_57223  P4  ctg_63866 ctg_63866  P5  ctg_123090  P6  ctg_111158  P7  ctg_117356 ctg_117356  P8  ctg_73782  P9  ctg_9446  ctg_9446  P10 ctg_25348  P11 ctg_104447  P12 ctg_2815  ctg_2815  P13 ctg_37852 ctg_37852  P14 ctg_61528 ctg_61528  P15 ctg_512 ctg_512 P16 ctg_111348 ctg_111348 P18 ctg_105149 P19 ctg_61472 ctg_61472 P20 ctg_44030 ctg_44030 P21 ctg_23999 ctg_23999 P23 ctg_29077 ctg_29077 P8  P18  P11  P1  P2  P7  P15  P20  P23  P3  P12  P14   LINC01006  PCAT1  LOC283177 This result highlights both the incompleteness of current cancer transcriptome datasets and the biological value of transcript information that can be extracted through adequate experimental (total stranded RNA-seq and NanoString quantification) and computational (DE-kupl) tools. The resulting signature demonstrated a sensitivity and robustness towards tumor risk surpassing the state of the art for discrimination of prostate cancer. Furthermore, the nine-probe RNA signature performed independently of tumor origin and clinico-pathological characteristics, but also independently of the technology used for RNA measurements. (ctg_117356), and P4 (ctg_63866) (Jiang et al. 2019) . In most cases, their function in gene expression regulation and chromatin configuration has not yet been investigated and experimentally validated, but it is tempting to speculate that defined senseantisense transcripts may influence a super-enhancer activity and, consequently, may fine-tune the expression of neighboring genes.
DISCUSSION
In this work, we propose DE-kupl as a tool for discovery of novel disease-associated transcriptomic variations, which can be further explored for biological and clinical relevance. As a pilot project, we oriented the pipeline towards the discovery of novel lncRNAs, but using proper masking and filtering criteria defined by the investigator,
METHODS
Tissue samples
Tumor and normal biopsy specimens were retrospectively collected from prostate cancer patients who provided informed consent and were approved for distribution by the H. Mondor institutional board (PAIR cohort). Tumors classification in low-, intermediate-and high-risk prognosis was performed according to Gleason and TNM scores and regardless PSA values (Supplemental Table S1 , S3).
RNA extraction, quantification and cDNA library production
Total RNA was extracted using the TRizol reagent (ThermoFisher), according to manufacturer's procedure, quantified and quality controlled using a 2100 Bioanalyzer (Agilent). RNA samples with RNA Integrity Number (RIN) above 6 were depleted for ribosomal RNA and converted into cDNA library using a TruSeq Stranded Total Library Preparation kit (Illumina). cDNA libraries were normalized using an Illumina Duplexspecific Nuclease (DSN) protocol prior to a paired-end sequencing on HiSeq™ 2500 (Illumina). At least 20x coverage per sample was considered as minimum of unique sequences for further data analysis.
RNA-sequencing data
Raw paired-end strand-specific RNA-seq data was generated by our laboratory from ribo-depleted total RNA samples of prostate tissues (8 normal and 16 tumor specimens;
Supplemental Computational workflow for reference-based ab initio transcripts assembly from total stranded RNA-seq dataset (HoLdUP)
The human genome version hg19 and the GENCODE v14 annotation were used in this study. First, we performed a quality control of all sequencing data by FastQC Babraham Bioinformatics software. Reads were mapped using TopHat 2.0.4, allowing 3 mismatches and requesting uniquely mapped reads which were further assembled using the BedTools suite. Overlapping contigs from all libraries were merged and only contigs supported by at least 10 reads in either library were further assembled in segments if mapped in the same strand and separated by less than 100 nucleotides. We compared segments to the GENCODE v14 annotation to extract antisense and intergenic TU longer than 200 nucleotides. To classify lncRNAs, we applied the following criteria: (i) an expression level above 0.2 quartile of mRNA expression in at least one condition per tissue (Class 2); (ii) within this class, all TUs containing at least one TopHatidentified exon-exon junction and at least one spliced EST from UCSC mapped contigs were assigned to Class 1. The whole catalog, the R code and Data Tables can be provided upon request.
Overlap between GENCODE, MiTranscriptome, DE-kupl and HoLdUp catalogues
Intersection between transcripts was counted only in case of 50% overlap of nucleotide sequence between genomic coordinates of each fragment.
Differential expression analysis
Read counting was performed on the compiled annotation (GENCODE v26, HoLdUp Class 1 and Class 2) for each sample, using featureCounts 1.6.0 with the following parameters: -F "SAF" -p -s 2 -O and the DESeq R package (Love et al. 2014) . Only RNAs with adjusted p-value below 0.01 were retained as differentially expressed to constitute the prostate tumor signature.
NanoString nCounter Expression Assay
100 ng of total RNA was used for direct digital detection of 29 target transcripts: 6
housekeeping genes (RPL11, GAPDH, NOL7, GPATCH3, ZNF2 and ZNF346), 23 contigs and the one known PCa-associated lncRNA, PCA3. Each target gene of interest was detected in RNA samples of 144 specimens (9 normal and 135 tumor) of the PAIR cohort (Supplemental Table S3 ) on NanoString nCounter V2 using reporter and capture probes of 35-to 50-nucleotide targeting sequences. Data was normalized through the use of NanoString's intrinsic positive controls and then contig expression was calculated relative to the average signal of three housekeeping genes (GPATCH3, ZNF2 and ZNF346). Raw and normalized data for each specimen, mean and fold change expression in normal against tumor samples are presented in Supplemental Table S4 and S5.
Contig expression measurements in TCGA-PRAD datasets
DE-kupl provides representative k-mers for each differentially expressed contig. We converted the TCGA-PRAD FASTQ files to k-mer counts using Jellyfish count and counted representative k-mers in each Jellyfish count file using the Jellyfish query command.
Counts were normalized by total number of reads in corresponding libraries. To determine whether counts of DE-kupl derived representative k-mer were a reliable proxy for evaluating contig expression, we compared representative k-mer counts to average counts from k-mers sampled along each contig. All individual counts were obtained using Jellyfish Dump files produced for each TCGA-PRAD library. Sampling was performed as follows: (i) we extracted all k-mers from the contig that were unique in the Ensembl human v91 transcript reference, and (ii) from this list we sampled 10 regularly spaced k-mers, starting from the first 10% and ending in the last 10% of the list. This sampling procedure was repeated four times for each contig. For the whole TCGA library and each contig, the 10 k-mer counts obtained by Jellyfish were averaged, yielding one average count per sample per library. Correlations between sample counts and representative k-mer counts are shown in Fig. S8 for two DE-kupl contigs. Pearson correlations between counts of representative k-mers and sampled k-mers from the same contig: for each contig, in the TCGA-PRAD datasets (N=557) the number of occurrences of (I) the representative DE-kupl k-mer and (II) of four sets of 10 k-mers sampled at regular distance along the length of the contig. Each sample (noted SAMPLE1-4) was obtained by changing the starting position of the first k-mer. RNA-seq reads profiling along a locus of interest was performed using our in-house R script VING (Descrimes et al. 2015) . The normal samples were assigned to the group "controls" and the tumor specimens -to the group "cases", with the assumption that the "cases" should have higher values than "controls".
RNA-sequencing data visualization
Unsupervised clustering of prostate specimens
Specimens were ranked based on the Log10(expression counts) levels of contigs assessed by the NanoString nCounter assay using a ComplexHeatmap R-package (Gu et al. 2016) .
Variable selection using the LASSO penalized logistic regression and external validation of signatures
Signature inference was performed in R using the normalized Selection Set (23 probes in 144 observations) as a variable selection dataset and contigs counts table of the Validation Set (23 probes in 557 observations) as an external validation dataset (R Core
Team). First, we performed penalized logistic regression using the glmnet R package to select probes predicting the tumor status on the Selection Set upsampled to correct the imbalance class distribution (9 normal versus 135 tumor specimens) (Friedman et al. 2010) . Selection was performed using all probes (signature_mixed including PCA3) or using only new-lnc RNA contigs only (signature_new-lnc) (Fig. S7) . Second, we built predictors using the boosted logistic regression from the caTools and caret packages (Tuszynski 2008) , (Kuhn 2008) . AUCs were computed using the precrec package on 100 training and testing datasets (Saito and Rehmsmeier 2017) , sub-sampled from the initial dataset (Normal vs. Tumor, Normal vs. HR, Normal vs. IR and Normal vs. LR) using the sample.split function from the caTools package.
DATA ACCESS
TCGA prostate cancer poly(A)-selected RNA-seq and corresponding clinical data can be obtained from TCGA portal (https://www.cancer.gov/tcga).
